Literature DB >> 29529128

Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.

C E McCoach, G M Blumenthal, L Zhang, A Myers, S Tang, R Sridhara, P Keegan, R Pazdur, R C Doebele, D Kazandjian.   

Abstract

Entities:  

Year:  2019        PMID： 29529128      PMCID： PMC6442647          DOI： 10.1093/annonc/mdy045

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

Review 1.  How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review.

Authors:  Jordi Remon; Jessica Menis; Antonin Levy; Dirk K M De Ruysscher; Lizza E L Hendriks
Journal:  Transl Lung Cancer Res       Date:  2021-07

Review 2.  Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm.

Authors:  Caroline Robert; Aurelien Marabelle; Hugo Herrscher; Caroline Caramella; Pascal Rouby; Karim Fizazi; Benjamin Besse
Journal:  Nat Rev Clin Oncol       Date:  2020-07-07       Impact factor: 66.675

3.  Depth of Response was Associated with Progression-Free Survival in Patients with Advanced Non-small Cell Lung Cancer treated with EGFR-TKI.

Authors:  Yu-Tao Liu; Kai Zhang; Cheng-Cheng Li; Xing-Sheng Hu; Jun Jiang; Xue-Zhi Hao; Yan Wang; Jun-Ling Li; Pu-Yuan Xing; Sheng Yang; Xin Zhang; Guo-Qiang Wang; Shang-Li Cai; Yuan-Kai Shi
Journal:  J Cancer       Date:  2019-08-28       Impact factor: 4.207

Review 4.  Research Progress and Challenges in the Treatment of Central Nervous System Metastasis of Non-Small Cell Lung Cancer.

Authors:  Bin Wang; Hanfei Guo; Haiyang Xu; Hongquan Yu; Yong Chen; Gang Zhao
Journal:  Cells       Date:  2021-10-01       Impact factor: 6.600
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.